157 related articles for article (PubMed ID: 27089726)
21. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
[TBL] [Abstract][Full Text] [Related]
22. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption.
Halleen JM; Alatalo SL; Suominen H; Cheng S; Janckila AJ; Väänänen HK
J Bone Miner Res; 2000 Jul; 15(7):1337-45. PubMed ID: 10893682
[TBL] [Abstract][Full Text] [Related]
23. [Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis].
Nowak Z; Konieczna M; Wańkowicz Z
Pol Merkur Lekarski; 2004 Aug; 17(98):138-41. PubMed ID: 15603322
[TBL] [Abstract][Full Text] [Related]
24. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
[TBL] [Abstract][Full Text] [Related]
25. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M
Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803
[TBL] [Abstract][Full Text] [Related]
26. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption.
Halleen JM; Alatalo SL; Janckila AJ; Woitge HW; Seibel MJ; Väänänen HK
Clin Chem; 2001 Mar; 47(3):597-600. PubMed ID: 11238321
[No Abstract] [Full Text] [Related]
27. [Tartrate resistant acid phosphatase].
Yoh K
Nihon Rinsho; 2004 Dec; 62 Suppl 12():215-9. PubMed ID: 15658303
[No Abstract] [Full Text] [Related]
28. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients.
Chao TY; Yu JC; Ku CH; Chen MM; Lee SH; Janckila AJ; Yam LT
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):544-50. PubMed ID: 15701839
[TBL] [Abstract][Full Text] [Related]
29. Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
Windrichova J; Fuchsova R; Kucera R; Topolcan O; Fiala O; Finek J; Slipkova D; Karlikova M; Svobodova J
Anticancer Res; 2016 Apr; 36(4):1973-8. PubMed ID: 27069189
[TBL] [Abstract][Full Text] [Related]
30. Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.
Kijima T; Fujii Y; Suyama T; Okubo Y; Yonese J; Fukui I
Int J Urol; 2008 Jun; 15(6):546-7. PubMed ID: 18489646
[TBL] [Abstract][Full Text] [Related]
31. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
32. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption.
Halleen JM; Tiitinen SL; Ylipahkala H; Fagerlund KM; Väänänen HK
Clin Lab; 2006; 52(9-10):499-509. PubMed ID: 17078477
[TBL] [Abstract][Full Text] [Related]
33. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients.
Chao TY; Ho CL; Lee SH; Chen MM; Janckila A; Yam LT
J Biomed Sci; 2004; 11(4):511-6. PubMed ID: 15153786
[TBL] [Abstract][Full Text] [Related]
34. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
35. [Effects of SERMs on bone health. SERM and metabolic markers of bone].
Takami M; Shimada H
Clin Calcium; 2010 Mar; 20(3):365-71. PubMed ID: 20190366
[TBL] [Abstract][Full Text] [Related]
36. [Development for the determination of band 5b tartrate-resistant acid phosphatase activity in serum].
Uchida K; Nakanishi M; Yoh K
Rinsho Byori; 2001 Jan; 49(1):51-5. PubMed ID: 11215484
[TBL] [Abstract][Full Text] [Related]
37. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
38. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
[TBL] [Abstract][Full Text] [Related]
39. Survival markers related to bone metastases in prostate cancer.
Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ
Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355
[TBL] [Abstract][Full Text] [Related]
40. [Bone metabolic marker for osteoporosis].
Shidara K; Inaba M
Nihon Rinsho; 2009 May; 67(5):927-31. PubMed ID: 19432111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]